Summary of NeuroPace Conference Call Company Overview - **Company**: NeuroPace - **Industry**: MedTech, specifically focused on neuromodulation for epilepsy treatment Key Points and Arguments Commercial Momentum and Growth Drivers - NeuroPace has experienced significant growth in its core RNS (Responsive Neurostimulation) business, particularly in focal drug-resistant epilepsy, driven by: 1. **Increased Adoption and Utilization**: Focus on comprehensive epilepsy centers has led to more prescriptions and higher utilization rates [5][6] 2. **Referral Management Improvements**: Investments in identifying and managing patient referrals have streamlined the diagnostic process [6] 3. **Commercial Execution**: Strengthened sales leadership and ongoing investments in the commercial team have contributed to growth [6] Market Position and Technology Differentiation - NeuroPace's RNS technology is unique as it is the only closed-loop neuromodulation device, allowing for real-time monitoring and tailored therapy for patients [7][10] - The company is focused on expanding clinical indications and developing a robust product pipeline to further differentiate its technology [10] 2026 Financial Outlook - Guidance for 2026 is projected at $98 million to $100 million, with potential upside driven by: - Increased productivity and focus of the sales force [12] - Introduction of new products like SeizureID, aimed at improving physician efficiency [13] - Anticipated approval of the idiopathic indication from the NAUTILUS trial [14] Patient Flow and Market Penetration - Approximately 75,000 patients cycle through comprehensive epilepsy centers annually, indicating a modest penetration rate for RNS implants [16] - No structural barriers are identified that limit penetration; the focus is on educating clinicians and patients to facilitate adoption [17] Project CARE Initiative - The initiative has successfully broadened access to RNS beyond Level 4 centers, improving education and referral processes [20][21] Reimbursement Landscape - Positive momentum in reimbursement, with stable DRG codes and efforts to enhance physician reimbursement for monitoring patients [24][26] - Approximately 20% of the payer mix consists of traditional Medicare, with 30% from Medicare Advantage and 50% from private payers [27] NAUTILUS Trial and FDA Submission - The PMA submission for the idiopathic generalized patient population has been accepted by the FDA, indicating a productive dialogue and high-quality submission [30] - The trial demonstrated a 77% median seizure reduction rate in a highly refractory population, with a low complication rate [36] Market Opportunity - In the U.S., there are about 3.6 million people with epilepsy, with 1.2 million classified as drug-resistant. The idiopathic generalized group represents a significant subsegment of this population [41][42] - The absence of approved devices for idiopathic generalized epilepsy positions NeuroPace to capture a substantial market share upon FDA approval [43] Commercial Strategy and Drug Interaction - NeuroPace aims to work alongside pharmaceutical advancements, recognizing that a significant portion of epilepsy patients remain drug-resistant despite numerous drug approvals [51][52] - The RNS System is designed to complement drug therapies, providing a unique approach to managing epilepsy [52] Additional Important Insights - The company is proactive in preparing for market access and reimbursement processes ahead of potential FDA approval, indicating a strategic approach to commercial readiness [46][48] - The focus on patient safety and efficacy in clinical trials is emphasized as a critical factor for clinician adoption and patient trust [35][36]

Core Insights - NeuroPace, Inc. (NPCE) is focused on growth through its RNS System, a brain-responsive implant aimed at reducing seizures in adults with drug-resistant focal epilepsy, with improved sales and margins expected in 2026 due to Medicare payment changes [2][11]. Product Overview - The RNS System is a closed-loop neuromodulation implant that monitors brain activity and delivers targeted stimulation to prevent seizures, with remote programming capabilities for clinicians [4][5]. - The system includes an implantable neurostimulator, tailored leads, and a patient remote monitor, along with a physician tablet and data management system [5]. Market and Demand - The primary market for the RNS System is adult patients with drug-resistant focal epilepsy, with an estimated U.S. addressable population of around 575,000 [8]. - Demand is driven by specialized epilepsy centers, with a reimbursement framework covering the implant procedure and ongoing monitoring, impacting over 200 million covered lives as of December 2024 [9]. Revenue Model - NeuroPace generates revenue from initial and replacement sales of the RNS System, linking growth to procedure volume and the installed base [7]. - The company reported $100 million in revenue for 2025, a 25% increase from 2024, with significant growth in prescribers and implanters [11][18]. Reimbursement Changes - Medicare reimbursement updates effective January 1, 2026, will increase physician payments for RNS procedures by approximately 43% and 45% for implants and replacements, respectively [12]. - Hospital reimbursement for RNS replacement procedures will rise to $31,526 from $21,444, enhancing the economic viability for hospitals and physicians [13]. Margin and Pricing Strategy - The company has maintained disciplined pricing strategies with low to mid-single-digit increases and improved manufacturing efficiencies, leading to a gross margin of 77.4% in Q4 2025 [15][16]. - For 2026, adjusted gross margin is projected to be between 81.5% and 82.5%, supported by ongoing pricing discipline and a cleaner revenue mix [17]. Future Outlook - For 2026, total revenue guidance is set at $98 million to $100 million, with RNS growth expected at 20% to 22%, excluding contributions from DIXI and idiopathic generalized epilepsy [20]. - The company anticipates typical seasonality in growth, with a projected revenue of $21 million to $22 million for Q1 2026 [21].

Core Insights - NeuroPace, Inc. (NPCE) achieved $100 million in revenue for 2025, reflecting a 25% year-over-year growth, with a focus on the core RNS System as non-core revenue diminishes [2][10] - The company anticipates continued growth in its adult focal RNS franchise, projecting at least 20% growth for 2026, aligning with its long-term strategy [3][10] - The stock is expected to perform in line with the market, emphasizing the importance of execution, valuation, and catalysts rather than merely identifying peak performance [3] Revenue and Business Transition - The 2025 revenue growth was supported by a shift towards the core RNS business, with DIXI Medical contributing approximately 16% of revenue, which will cease after inventory sell-through by the end of 2025 [4][11] - The transition to a "pure-play" RNS model is expected to enhance profitability and operational focus, as DIXI revenue will no longer be recorded post-2025 [11][12] Operational Growth and Market Dynamics - Management highlights the expansion of growth channels beyond Level 4 comprehensive epilepsy centers, which is crucial for accelerating procedure-based adoption [5] - Medicare's reimbursement updates effective January 1, 2026, significantly increase hospital and physician payments for RNS procedures, which could enhance adoption and procedure growth [13][14] Financial Metrics and Valuation - NPCE trades at approximately 4.57x forward 12-month sales per share, above the Zacks sub-industry average of 4.11x and the Medical sector at 2.28x, but below the S&P 500 at 5.06x [6] - The company’s gross margin improved to 77.4% in Q4 2025, with RNS gross margin at 80.5%, and is expected to reach 81.5%–82.5% in 2026 [12] Near-Term Challenges - The company anticipates adjusted EBITDA losses between $9 million to $11 million in 2026, with operating expenses projected at $90 million to $92 million, primarily in the first half of the year [15] - Revenue growth is expected to be moderated in the first half of 2026, with guidance of $21 million to $22 million for Q1, potentially impacting investor sentiment [16] Investment Framework - The investment outlook suggests a focus on whether fundamentals can improve sufficiently to justify the current premium valuation compared to historical sales multiples [17]

Core Insights - NeuroPace, Inc. (NPCE) is evolving from a device-centric model to incorporating software and workflow tools aimed at enhancing clinician capacity and expanding the eligible patient pool over time [1] Group 1: AI and Software Integration - NeuroPace is integrating artificial intelligence features as a workflow enhancement rather than a separate revenue stream, with the goal of reducing physician review time and increasing patient management efficiency without additional costs [2] - The company plans to migrate its clinician platform to the cloud to facilitate rapid deployment of software capabilities, which can enhance adoption and maintain consistent updates across various sites [3] Group 2: Seizure ID and Remote Care - Seizure ID is positioned as a near-term AI catalyst, submitted for FDA approval in Q4 2025, with expectations for clearance in the first half of 2026 [4] - The Seizure ID feature aims to alleviate the data-review burden in epilepsy practices, thereby expediting clinical decisions and follow-ups, and will be integrated into the RNS platform at no additional subscription fee [5] - Remote Care is targeted for regulatory submission in 2026, designed to enhance telehealth programming and follow-up efficiency, which can help clinics manage more patients without increasing operational costs [6][7] Group 3: Expansion and Market Strategy - The largest demand-expansion lever is the idiopathic generalized epilepsy indication, with a premarket approval supplement filed on December 15, 2025, currently under FDA review [8][9] - The company is focusing on expanding its reach beyond Level 4 comprehensive epilepsy centers through Project CARE, which includes targeted investments and enhanced nurse navigator support to improve access and throughput [12] - Successful execution of community site onboarding is critical, requiring sustained training and development of referral networks to ensure consistent care quality [13] Group 4: Future Monitoring and Expectations - Key performance indicators for 2026 include evidence of growth in prescribers and patients, regulatory progress on Seizure ID, and plans for Remote Care submission [15] - Early signs of coverage and training readiness for the idiopathic generalized epilepsy review will be crucial for advancing the approval process and expanding payer coverage [10]

Core Viewpoint - NeuroPace, Inc. is set to present at the Leerink 2026 Global Healthcare Conference, highlighting its focus on transforming the lives of individuals with epilepsy through innovative medical devices [1] Company Overview - NeuroPace, Inc. is based in Mountain View, California, and specializes in medical devices aimed at reducing or eliminating seizures in epilepsy patients [1] - The company’s RNS System is the first and only commercially available brain-responsive platform that provides personalized, real-time treatment at the source of seizures [1] Financial Performance - For the fourth quarter of 2025, NeuroPace reported total revenue of $26.6 million, marking a 24% increase compared to the fourth quarter of 2024 [1] - Revenue from the RNS System reached $22.4 million, reflecting a growth of 26% compared to the same period in the previous year [1]

Core Viewpoint - NeuroPace is experiencing positive market activity following its latest earnings release, which showed significant revenue growth and a reduction in net loss [1][2]. Financial Performance - In Q4 2025, NeuroPace reported revenue of $26.6 million, a 24% increase compared to Q4 2024 [2]. - The company narrowed its net loss to $2.7 million ($0.08 per share) from a loss of nearly $5.3 million in the previous year [2]. - The consensus analyst estimates were surpassed, with expected revenue of $24.4 million and a net loss per share of $0.18 [4]. Revenue Drivers - Growth was attributed to favorable Medicare reimbursement decisions and an increase in prescribers and accounts [4]. - The RNS System, an epilepsy treatment device, was the main revenue driver, with sales rising 26% to over $22 million [4]. Future Guidance - Management provided guidance for full-year 2026 revenue between $98 million and $100 million, with a non-GAAP EBITDA loss projected at $9 million to $10 million [5]. - This guidance reflects a decrease from the 2025 figures of $100 million in revenue and a $5 million EBITDA loss [5]. Market Sentiment - Despite the positive quarterly performance, the future guidance was perceived as less impressive, contributing to a muted investor reaction [6]. - The RNS System is recognized as a unique and winning product, suggesting potential for the stock [6].

分组1 - NeuroPace, Inc. reported a quarterly loss of $0.08 per share, better than the Zacks Consensus Estimate of a loss of $0.14, and improved from a loss of $0.18 per share a year ago, resulting in an earnings surprise of +41.48% [1] - The company achieved revenues of $26.59 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 2.47%, and showing an increase from $21.47 million in the same quarter last year [2] - NeuroPace has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates four times during the same period [2] 分组2 - The stock has underperformed the market, losing about 8.4% since the beginning of the year, while the S&P 500 has gained 0.5% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.23 on revenues of $21.7 million, and for the current fiscal year, it is -$0.71 on revenues of $98.65 million [7] - The Medical - Instruments industry, to which NeuroPace belongs, is currently in the top 33% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Core Insights - NeuroPace reported a total revenue of $26.6 million for Q4 2025, reflecting a 24% year-over-year increase, primarily driven by RNS System sales which reached $22.4 million, up 26% from the previous year [3][7] - The company anticipates a long-term growth trajectory of at least 20% in its core RNS business within the current adult focal epilepsy indication [2] - For the full year 2025, total revenue was $100 million, a 25% increase year-over-year, with RNS System sales also up 25% [12] Financial Performance - Gross margin for Q4 was 77.4%, an improvement from 75.4% in the prior year, driven by higher-margin RNS revenue and improved manufacturing efficiency [8] - Adjusted EBITDA was positive at $0.9 million for the second consecutive quarter, with a net loss of $2.7 million, improved from $5.3 million a year earlier [9][13] - Operating expenses for Q4 were $22.3 million, up from $19.8 million a year ago, but growth remained below revenue growth, indicating operational leverage [9] Regulatory and Product Development - The FDA accepted a PMA supplement to expand RNS into idiopathic generalized epilepsy, with a 180-day review period initiated [5][20] - The AI-enabled SeizureID platform is expected to be approved in H1 2026, aimed at enhancing clinician efficiency [5][22] - NeuroPace is also advancing remote care initiatives, allowing physicians to adjust therapy settings during telehealth visits [23] Future Guidance - For 2026, the company reiterated revenue guidance of $98–100 million on a continuing-operations basis, implying underlying RNS growth of 20–22% [6][15] - The company expects adjusted operating expenses of $90–92 million and an adjusted EBITDA loss of $9–10 million for 2026 [19] - For Q1 2026, revenue is expected to be between $21 million and $22 million, with growth rates typically moderating in the first half of the year [16]

Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $26.6 million, representing a 24% year-over-year growth compared to $21.5 million in the prior year quarter [4][18] - RNS System revenue was $22.4 million, up 26% year-over-year, contributing significantly to overall revenue growth [4][18] - Gross margin improved to 77.4%, up from 75.4% in the fourth quarter of 2024, driven by higher margin RNS revenue and manufacturing efficiencies [19] - Adjusted EBITDA was positive at $900,000 for the fourth quarter, marking a $1.9 million improvement year-over-year [22] Business Line Data and Key Metrics Changes - The core RNS business showed strong performance with a growth rate of 29% in the second half of 2025 [5] - Service revenue from data collaborations totaled approximately $890,000 in the fourth quarter [18] - Revenue from DIXI Medical was approximately $3 million, a decline of 4% compared to the fourth quarter of 2024, as the company worked to sell existing inventory before the end of the commercial partnership [18] Market Data and Key Metrics Changes - The majority of growth came from Level 4 centers, indicating increased adoption and utilization of the RNS System [6] - The company reached new highs in prescribers, accounts, and patient pipeline, reflecting broad-based momentum across the business [5] Company Strategy and Development Direction - The company is focused on deepening adoption within the adult focal epilepsy indication while preparing for future indication expansion [5] - Investments are being made in the commercial organization, including sales representative additions and nurse navigator resources to enhance patient navigation through the treatment process [9] - The company aims to expand its RNS therapy access through community pathways and improve referral management [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving a long-term growth trajectory of at least 20% in the core RNS business [7] - The company reiterated its full-year 2026 revenue guidance of $98 million to $100 million, assuming core RNS growth of 20%-22% [8][26] - Management highlighted the potential for a transformational year in 2026, driven by ongoing market momentum and new product developments [17][34] Other Important Information - The company submitted a PMA supplement to the FDA for an expanded indication in idiopathic generalized epilepsy (IGE), supported by significant clinical data [10] - The SeizureID tool, designed to enhance physician workflow and improve patient outcomes, is expected to receive approval in the first half of 2026 [12] Q&A Session Summary Question: How quickly can the company translate from IGE approval to revenue collection? - Management indicated that extending coverage in the private payer community is essential and that preparations are already underway to target key payers [38] Question: What is the impact of pricing on RNS growth in the fourth quarter? - Management noted that mid-single digit pricing increases have been consistent, contributing positively to gross margins without any significant changes in Q4 [50] Question: What is the current state of capacity dynamics across implanting centers? - Management stated that there is sufficient capacity in the channel for prescribers and that nurse navigators are being employed to facilitate patient flow through the referral process [60][61] Question: What is the logistics behind the SeizureID opportunity? - SeizureID will be part of the RNS System offering, aimed at improving efficiency for clinicians without additional costs for access [66]

Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $26.6 million, representing a 24% year-over-year growth compared to $21.5 million in the prior year quarter [5][22] - RNS System revenue was $22.4 million, up 26% year-over-year, reflecting strong performance in the core business [6][22] - Gross margin improved to over 77%, up approximately 200 basis points year-over-year, driven by manufacturing efficiencies [9][24] - Adjusted EBITDA was positive at $900,000 in the fourth quarter, marking a $1.9 million improvement compared to the prior year quarter [28] Business Line Data and Key Metrics Changes - The majority of revenue growth continues to come from Level 4 centers, with RNS growth in the second half of 2025 at 29% [8] - Service revenue tied to data collaborations totaled approximately $890,000 in the fourth quarter [22] - Revenue from DIXI Medical was approximately $3 million, representing a decline of 4% compared to the fourth quarter of 2024 [22] Market Data and Key Metrics Changes - The company is focused on expanding access to RNS therapy through community pathways and referral pathways, which are contributing to growth [6][8] - The adult focal epilepsy market remains a significant opportunity, with ongoing efforts to deepen adoption and utilization [6][39] Company Strategy and Development Direction - The company aims to grow a minimum of 20% in its core RNS business with the current adult focal epilepsy indication [9] - Strategic investments are being made in the commercial organization, including sales representative additions and nurse navigator resources [11][20] - The company is pursuing an expanded indication for the RNS System in idiopathic generalized epilepsy (IGE) and has submitted a PMA supplement to the FDA [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth trajectory and the potential for a transformational 2026 [10][20] - The company is optimistic about the upcoming approval for IGE and the associated market opportunities [41][55] - Management highlighted the importance of ongoing investments in product development and clinical programs to enhance the RNS System's capabilities [42] Other Important Information - The company plans to report DIXI-related financial results as discontinued operations starting in Q1 2026 [30][31] - Full year 2026 revenue guidance is reiterated at $98 million-$100 million, excluding contributions from DIXI [32] Q&A Session Summary Question: Can you provide details on the timeline from approval to revenue collection for the generalized opportunity? - Management indicated that extending coverage in the private payer community is crucial and that preparations are already underway [46] Question: What is the magnitude of pricing impact on RNS growth in the fourth quarter? - Management noted consistent mid-single digit pricing increases annually, with no significant changes in Q4 [61] Question: What are the current dynamics regarding capacity across implanting centers? - Management stated that there is sufficient capacity in the channel for prescribers and that nurse navigators are being utilized to streamline patient flow [70][72] Question: Can you elaborate on the Seizure ID opportunity and its implementation? - Seizure ID will be part of the RNS System offering, aimed at improving clinician efficiency without additional costs [79]